This individually randomized telemedicine-based trial aims to evaluate the efficacy of a single dose of azithromycin for prevention of progression of COVID-19 in patients with a recent positive SARS-CoV-2 test who are not currently hospitalized.
Coronavirus disease 2019 (COVID-19) is a respiratory illness that can spread from person to person. The virus that causes COVID-19 is a novel coronavirus that was first identified during an investigation into an outbreak in Wuhan, China.
Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 2271 participants
Primary Purpose: Treatment
Estimated Study Start Date: April 1, 2020
Estimated Study Completion Date: July 30, 2021
Arm 1: Azithromycin
Participants will be shipped a single 1 g dose of oral azithromycin
Arm 2: Placebo
Participants will be shipped a dose of matching placebo
Thank you for your interest in advancing COVID-19 research.
Please fill out this contact form to be connected to a member of the study team. The following information that you enter will only be authorized to be shared with the research team conducting this specific study.
If you have any difficulties or questions, please contact our support specialists at [email protected]
For general questions about COVID-19 clinical trials, please email [email protected] For study specific inquiries, submit the interest form and you'll be connected to the team.